Many research groups have reported that BRCA1 and BRCA2 mutation carriers are more likely to develop a more aggressive prostate cancer phenotype, generally associated with a higher probability of nodal involvement, distant metastasis, and low grade tumours [7, 8]. This evidence concerns the gene BRCA2 and prostate carcinoma.